Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® ▼ (abemaciclib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
What was the incidence and management of venous thromboembolic events with Verzenios® ▼ (abemaciclib) in early breast cancer?
Venous thromboembolic events were reported in 2.5% of patients in the abemaciclib arm, compared to 0.6% in the ET alone arm of monarchE, and was managed with dose reductions, dose holds and anticoagulation therapy.
UK_cFAQ_ABE045_VTE_EBC
en-GB
Management recommendations for Venous thromboembolic events (VTEs) in early breast cancer
Dose modification and management recommendations are summarized inDose Modification and Management - VTEs .
CTCAE Grade |
Abemaciclib Dose Modifications |
Grade 1, 2, 3, or 4 |
Suspend dose and treat as clinically indicated. Abemaciclib may be resumed when the patient is clinically stable. |
Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; VTEs = venous thromboembolic events.
Venous thromboembolic events in monarchE
The Khorana score, summarized in The Khorana Scoring System, was utilized to determine the baseline risk of a venous thromboembolic event (VTE) for patients enrolled in monarchE.2
Patient Characteristics |
Score |
|
1 point |
|
2 points |
|
1 point |
|
1 point |
|
1 point |
|
1 point |
Total combined points |
Patients are divided into low risk (0 points), intermediate risk (1-2 points), and high risk (≥3 points) based on the scoring system.3